By selectively targeting DPAGT1, MA1 has the potential to become the first-in-class therapeutic inhibitor of this enzyme, thereby impairing N-glycan biosynthesis in cancer cells while minimizing adverse effects on normal tissues. The gene discussed is PNMA1; the disease is cancer.